Background/Aims: Vildagliptin is an oral inhibitor of dipeptidyl peptidase-4, an enzyme
mainly responsible for inactivating incretins, and one of the widely used drugs for the …

Vildagliptin is a potent and selective inhibitor of dipeptidyl peptidase-IV (DPP-4), orally
active, that improves glycemic control in patients with type 2 diabetes (T2DM) primarily by …

Background To assess the efficacy of a vildagliptin and metformin combination therapy to a
metformin monotherapy in type 2 diabetes mellitus patients. Methods: Sixty-one patients with …

Vildagliptin is a potent, selective and reversible inhibitor of dipeptidyl peptidase‐4 (DPP‐4),
the enzyme responsible for rapid inactivation of the incretin hormones glucagon‐like peptide …

Objective: To compare the effects of either vildagliptin or glimepiride on glycemic variability,
oxidative stress, and endothelial parameters in patients with type 2 diabetes mellitus (T2DM) …

Diabetes mellitus (DM) is one of the most common chronic disorders, with increasing
prevalence worldwide. Type 2 diabetes (T2DM), a multifaceted disease involving multiple …

Objective: To evaluate the action of vildagliptin+ metformin on some adipocytokine levels,
glycemic control, and β-cell function in type 2 diabetic patients. Research design and …

Vildagliptin is a new oral antidiabetic agent that enhances pancreatic islet cell
responsiveness to glucose. An extensive clinical program involving approximately 22,000 …

Dipeptidyl peptidase-4 inhibitors are known to lower glucose levels and are also beneficial
in the management of cardiovascular disease. Here, we investigated whether a dipeptidyl …

Vildagliptin (Galvus®) is an antihyperglycaemic agent that selectively inhibits the dipeptidyl
peptidase-4 (DPP-4) enzyme. Such inhibition prevents the degradation of the incretin …